Published in AIDS on August 01, 1997
Adverse effects of antiretroviral therapy for HIV infection. CMAJ (2004) 2.04
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci (2007) 1.07
Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care (2003) 1.01
Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS (2000) 0.99
Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV. Wien Klin Wochenschr (2003) 0.77
Characteristics of hepatitis C virus infection in HIV-infected people. Can J Infect Dis (2001) 0.75
The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T. Aging Dis (2017) 0.75
Hyperlactatemia and human immunodeficiency virus infection: lessons from the era of antiretroviral monotherapy. Antimicrob Agents Chemother (2002) 0.75
[Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment]. Pathologe (2004) 0.75
Serum IgG subclass concentrations in healthy adults: a study using monoclonal antisera. Clin Exp Immunol (1984) 1.99
Systemic antibody deficiency in patients without serum immunoglobulin deficiency or with selective IgA deficiency. Clin Exp Immunol (1984) 1.48
Chain shortening of palmitic acid in human subjects. Am J Clin Nutr (1988) 1.39
Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol (1993) 1.39
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS (1998) 1.38
Cerebral mass lesions due to cytomegalovirus in patients with AIDS: report of two cases. J Infect (1995) 1.38
Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol (1984) 1.37
Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med (2002) 1.26
Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM (2003) 1.16
Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol (2001) 1.11
Exposure to blood borne infections in health care workers. Med J Aust (1992) 1.10
Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol (2001) 1.10
The IgG4 subclass is associated with a low affinity antibody response to tetanus toxoid in man. Immunology (1985) 1.05
Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis (2001) 1.05
Protein losing enteropathy due to systemic lupus erythematosus. Gut (1984) 1.02
Major histocompatibility complex genes influence the outcome of HIV infection. Ancestral haplotypes with C4 null alleles explain diverse HLA associations. Hum Immunol (1990) 0.99
Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. J Clin Microbiol (2011) 0.98
Eye injuries among pennant squash players and their attitudes towards protective eyewear. Med J Aust (1991) 0.98
Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic lupus erythematosus. J Clin Lab Immunol (1985) 0.96
Immune complexes in systemic sclerosis; detection by C1q binding, K-cell inhibition and Raji cell radioimmunoassays. J Clin Lab Immunol (1983) 0.95
Epidemiology of late presentation of HIV infection in Western Australia. Med J Aust (1992) 0.95
Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease. J Antimicrob Chemother (2006) 0.93
An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol (2001) 0.93
Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Immunol Methods (2012) 0.92
Successful pregnancy following steroid therapy and plasma exchange in a woman with anti-Ro (SS-A) antibodies. Case report. Br J Obstet Gynaecol (1987) 0.92
MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum Immunol (2001) 0.91
Immunoglobulin G subclass distribution of autoantibodies in systemic sclerosis, primary biliary cirrhosis, and overlap syndromes. Ann Rheum Dis (1987) 0.91
Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials (2003) 0.90
Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. Diabetologia (2009) 0.89
The frequency of high-grade intraepithelial neoplasia in anal/perianal warts is higher than previously recognized. Int J STD AIDS (2007) 0.89
GM phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum. Hum Immunol (1996) 0.88
Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med (2004) 0.88
Percentage of CD3+CD4-CD8-gammadeltaTCR- T cells is increased HIV disease. AIDS Res Hum Retroviruses (2001) 0.87
Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust (1998) 0.87
Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS (1996) 0.86
Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery. Antimicrob Agents Chemother (1982) 0.86
Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol (1998) 0.85
Association of IgA deficiency with HLA A28 and B14. Tissue Antigens (1983) 0.84
MHC genes and HIV infection. Lancet (1990) 0.84
Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2000) 0.84
A calibration material for IgG subclass assay. J Clin Lab Immunol (1984) 0.83
Mycobacterium avium infection and immune restoration disease after highly active antiretroviral therapy in a patient with HIV and normal CD4+ counts. Eur J Clin Microbiol Infect Dis (2001) 0.82
Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. AIDS (1994) 0.81
Pyomyositis complicating the acquired immunodeficiency syndrome. A report of two cases with coexistent neutropenia. Med J Aust (1991) 0.81
Systemic lupus erythematosus and Klinefelter's syndrome. Ann Rheum Dis (1983) 0.81
Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother (1981) 0.81
An investigation into the effect of the IgG antibody system on the susceptibility of IgA-deficient patients to respiratory tract infections. Clin Exp Immunol (1986) 0.81
Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy. AIDS (1993) 0.81
Serum and tissue concentrations of cefoxitin and cefamandole in women undergoing hysterectomy. Obstet Gynecol (1983) 0.81
Coronary heart disease is associated with regional grey matter volume loss: implications for cognitive function and behaviour. Intern Med J (2008) 0.80
Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.80
Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther (1981) 0.80
Severity and outcome of Pneumocystis carinii pneumonia (PCP) in patients of known and unknown HIV status. J Acquir Immune Defic Syndr (1994) 0.80
Glomerulonephritis and IgA deficiency. Clin Nephrol (1987) 0.79
Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. Curr HIV/AIDS Rep (2014) 0.79
Serum immune complexes in systemic sclerosis: relationship with precipitating nuclear antibodies. Ann Rheum Dis (1985) 0.79
Nephrotic syndrome in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis. Pathology (2000) 0.79
High circulating levels of soluble CD30 correlate with impaired delayed-type hypersensitivity responses in HIV-infected patients. AIDS (1999) 0.78
The effect of palmitic acid on lipoprotein cholesterol levels. Int J Food Sci Nutr (2000) 0.78
Phosphatidylcholine metabolism after transfer from lipid emulsions injected intravenously in rats. Implications for high-density lipoprotein metabolism. Biochim Biophys Acta (1989) 0.78
Platelet monoamine oxidase activity in patients with Huntington's disease. Clin Exp Pharmacol Physiol (1987) 0.78
Platelet monoamine oxidase: low activity in cigarette smokers. Psychiatry Res (1987) 0.78
18F-fluorodeoxyglucose positron emission tomography imaging in brain tumours: the Western Australia positron emission tomography/cyclotron service experience. J Med Imaging Radiat Oncol (2008) 0.77
Use of deuterium oxide to measure de novo fatty acid synthesis in normal subjects consuming different dietary fatty acid composition1. Biochim Biophys Acta (1998) 0.77
Cholesterolaemic influence of palmitic acid in the sn-1, 3 v. the sn-2 position with high or low dietary linoleic acid in healthy young men. Br J Nutr (2007) 0.77
The effect of palmitic acid on lipoprotein cholesterol levels and endogenous cholesterol synthesis in hyperlipidemic subjects. Lipids (1999) 0.76
Platelet monoamine oxidase activity and cigarette smoking. J Affect Disord (1982) 0.76
Immune restoration disease in HIV-infected patients after antiretroviral therapy. Clin Infect Dis (2001) 0.76
Protein-losing enteropathy in systemic lupus erythematosus. Aust N Z J Med (1988) 0.75
Leiomyoma of the oesophagus in an HIV-infected patient. Australas Radiol (2001) 0.75
Primary immunoglobulin deficiency and haematological disorders. Postgrad Med J (1983) 0.75
Lymphadenopathy and selective IgA deficiency. Br Med J (Clin Res Ed) (1984) 0.75
Periodontal attachment loss in HIV-infected patients is associated with the major histocompatibility complex 8.1 haplotype (HLA-A1,B8,DR3). Tissue Antigens (1999) 0.75
Antibody responses to tetanus toxoid in patients with primary biliary cirrhosis. J Clin Pathol (1987) 0.75
Follow-up for a fearful patient. Adv Nurse Pract (2001) 0.75
Enterovirus associated neurological disease in an HIV-1 infected man. J Neurovirol (1998) 0.75
Normal unstimulated lymphocytes produce granulopoietic inhibitory activity. Exp Hematol (1991) 0.75
Managing HIV. Part 4: Primary therapy. 4.2 Immune-based therapy for HIV infection. Med J Aust (1996) 0.75
When do patients present with HIV infection? Med J Aust (1993) 0.75
Cough and glaucoma: a possible association. Aust N Z J Med (1994) 0.75
Peyronie's disease in men with HIV responding to highly active antiretroviral therapy. HIV Med (2004) 0.75
Palmitic acid effect on lipoprotein profiles and endogenous cholesterol synthesis or clearance in humans. Asia Pac J Clin Nutr (1997) 0.75
Test and teach. Number seventy-two. Diagnosis: Bacillary angiomatosis. Pathology (1993) 0.75
Increasing the dietary polyunsaturated fat content alters whole-body utilization of 16:0 and 10:0. Am J Clin Nutr (1995) 0.75
Multiple pneumatocoeles and bilateral tension pneumothoraces complicating pneumocystis pneumonia in AIDS. Aust N Z J Med (1990) 0.75
Distribution of human CD30 gene promoter microsatellite alleles in healthy and human immunodeficiency virus-1 infected populations. Eur J Immunogenet (2003) 0.75